Chronic myeloid leukemia: Clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression

Seminars in Oncology

Volumn 39, Issue 1, 2012, Pages 58-66

  Ernst, Thomas ^a   Hochhaus, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DISEASE COURSE; GENOMIC INSTABILITY; HUMAN; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION;

EID: 84856396323     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.11.002     Document Type: Article

References (83)

1. J.M. Goldman, J.V. Melo Chronic myeloid leukemiaadvances in biology and new approaches to treatment N Engl J Med 349 2003 1451 1464 (Pubitemid 37211061)
2. B.J. Druker, S. Tamura, E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
3. T.G. Lugo, A.M. Pendergast, A.J. Muller, O.N. Witte Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1990 1079 1082
4. B.J. Druker, M. Talpaz, D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037 (Pubitemid 32267972)
5. A. Hochhaus, P. La Rose Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance Leukemia 18 2004 1321 1331 (Pubitemid 39136739)
6. T. O'Hare, C.A. Eide, M.W. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2007 2242 2249 (Pubitemid 47523141)
7. M. Talpaz, N.P. Shah, H. Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541 (Pubitemid 43882349)
8. H. Kantarjian, F. Giles, L. Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551 (Pubitemid 43882350)
9. M. Baccarani, J. Cortes, F. Pane Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
10. S. Branford, L. Fletcher, N.C. Cross Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 2008 3330 3338
11. M.C. Mller, N.C. Cross, P. Erben Harmonization of molecular monitoring of CML therapy in Europe Leukemia 23 2009 1957 1963
12. R. Hehlmann, A. Hochhaus, M. Baccarani European LeukemiaNet Chronic myeloid leukaemia Lancet 370 2007 342 350 (Pubitemid 47094995)
13. J.V. Melo, D.J. Barnes Chronic myeloid leukaemia as a model of disease evolution in human cancer Nat Rev Cancer 7 2007 441 453 (Pubitemid 46823444)
14. M. Baccarani, G. Saglio, J. Goldman Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820 (Pubitemid 44394987)
15. S.G. O'Brien, F. Guilhot, R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004 (Pubitemid 36302244)
16. A. Hochhaus, S.G. O'Brien, F. Guilhot Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
17. R.T. Silver, J. Cortes, R. Waltzman, M. Mone, H. Kantarjian Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials Haematologica 94 2009 743 744
18. F. Palandri, F. Castagnetti, G. Alimena The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up Haematologica 94 2009 205 212
19. F. Palandri, F. Castagnetti, N. Testoni Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up Haematologica 93 2008 1792 1796
20. J.F. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1018 1029 (Pubitemid 47629897)
21. S.M. Graham, H.G. Jørgensen, E. Allan Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325
22. D.W. Sherbenou, O. Hantschel, I. Kaupe BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib Blood 116 2010 3278 3285
23. A.S. Corbin, P. La Rose, E.P. Stoffregen, B.J. Druker, M.W. Deininger Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 101 2003 4611 4614 (Pubitemid 36857835)
24. S. Branford, Z. Rudzki, S. Walsh Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283 (Pubitemid 36759665)
25. A. Hochhaus, S. Kreil, A.S. Corbin Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2002 2190 2196 (Pubitemid 35331833)
26. S. Soverini, G. Martinelli, G. Rosti ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia J Clin Oncol 23 2005 4100 4109 (Pubitemid 46211315)
27. I.J. Griswold, M. MacPartlin, T. Bumm Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Mol Cell Biol 26 2006 6082 6093 (Pubitemid 44204527)
28. B.J. Skaggs, M.E. Gorre, A. Ryvkin Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants Proc Natl Acad Sci U S A 103 2006 19466 19471 (Pubitemid 46026054)
29. N.P. Shah, B.J. Skaggs, S. Branford Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency J Clin Invest 117 2007 2562 2569 (Pubitemid 47494357)
30. J.S. Khorashad, L.H. de, J.F. Apperley Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression J Clin Oncol 26 2008 4806 4813
31. E. Jabbour, H. Kantarjian, D. Jones Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 2006 1767 1773 (Pubitemid 44574988)
32. T. Lahaye, B. Riehm, U. Berger Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 2005 1659 1669 (Pubitemid 40490027)
33. S. Soverini, S. Colarossi, A. Gnani Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 2006 7374 7379 (Pubitemid 46095411)
34. T. Ernst, P. Erben, M.C. Muller Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica 93 2008 186 192 (Pubitemid 351397706)
35. J.S. Khorashad, M. Anand, D. Marin The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib Leukemia 20 2006 658 663
36. S.G. Willis, T. Lange, S. Demehri High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2005 2128 2137 (Pubitemid 41291730)
37. C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018 (Pubitemid 34832631)
38. S. Chu, H. Xu, N.P. Shah Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood 105 2005 2093 2098 (Pubitemid 40731797)
39. G.R. Angstreich, W. Matsui, C.A. Huff Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors Br J Haematol 130 2005 373 381 (Pubitemid 43899585)
40. L.J. Elrick, H.G. Jorgensen, J.C. Mountford, T.L. Holyoake Punish the parent not the progeny Blood 105 2005 1862 1866 (Pubitemid 40731765)
41. J. Cortes, E. Jabbour, H. Kantarjian Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 2007 4005 4011 (Pubitemid 350248456)
42. S. Soverini, A. Gnani, S. Colarossi Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Blood 114 2009 2168 2171
43. M.C. Mller, J.E. Cortes, D.W. Kim Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations Blood 114 2009 4944 4953
44. T. Hughes, G. Saglio, S. Branford Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase J Clin Oncol 27 2009 4204 4210
45. T. Ernst, F.X. Gruber, O. Pelz-Ackermann A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib Haematologica 94 2009 1227 1235
46. T. Hughes, M. Deininger, A. Hochhaus Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37 (Pubitemid 43990609)
47. S. Branford, Z. Rudzki, I. Parkinson Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2004 2926 2932 (Pubitemid 39434981)
48. L. Wang, K. Knight, C. Lucas, R.E. Clark The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia Haematologica 91 2006 235 239
49. R.D. Press, S.G. Willis, J. Laudadio, M.J. Mauro, M.W. Deininger Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood 114 2009 2598 2605
50. M.E. Gorre, M. Mohammed, K. Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880 (Pubitemid 32743979)
51. N.P. Shah, J.M. Nicoll, B. Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125 (Pubitemid 41039112)
52. S. Branford, Z. Rudzki, S. Walsh High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475 (Pubitemid 34525335)
53. M.W. Deininger, L. McGreevey, S. Willis, T.M. Bainbridge, B.J. Druker, M.C. Heinrich Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography Leukemia 18 2004 864 871 (Pubitemid 38500206)
54. S. Soverini, G. Martinelli, M. Amabile Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib Clin Chem 50 2004 1205 1213 (Pubitemid 38824229)
55. J.A. Irving, S. O'Brien, A.L. Lennard, L. Minto, F. Lin, A.G. Hall Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib Clin Chem 50 2004 1233 1237 (Pubitemid 38824234)
56. N. Sorel, F. Chazelas, A. Brizard, J.C. Chomel Double-gradient- denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients Clin Chem 51 2005 1263 1266 (Pubitemid 43079409)
57. K.M. Polkov, T. Lopotov, H. Klamov, J. Moravcov High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain Leuk Res 32 2008 1236 1243
58. A. Vivante, N. Amariglio, M. Koren-Michowitz High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations Leukemia 21 2007 1318 1321 (Pubitemid 46831827)
59. V.G. Oehler, J. Qin, R. Ramakrishnan Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR Leukemia 23 2009 396 399
60. K.A. Kreuzer, P. Le Coutre, O. Landt Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique Ann Hematol 82 2003 284 289 (Pubitemid 36701422)
61. F.X. Gruber, T. Lamark, A. Anonli Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL Leukemia 19 2005 2159 2165 (Pubitemid 41741610)
62. O. Pelz-Ackermann, M. Cross, H. Pfeifer Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR Leukemia 22 2008 2288 2291
63. S. Preuner, D. Denk, F. Frommlet, M. Nesslboeck, T. Lion Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR) Leukemia 22 2008 1956 1961
64. T. Ernst, J. Hoffmann, P. Erben ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Haematologica 93 2008 1389 1393
65. B. Calabretta, D. Perrotti The biology of CML blast crisis Blood 103 2004 4010 4022 (Pubitemid 38685338)
66. H. Ahuja, M. Bar-Eli, S.H. Advani, S. Benchimol, M.J. Cline Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia Proc Natl Acad Sci U S A 86 1989 6783 6787 (Pubitemid 19236343)
67. E. Feinstein, G. Cimino, R.P. Gale p53 in chronic myelogenous leukemia in acute phase Proc Natl Acad Sci U S A 88 1991 6293 6297 (Pubitemid 21914932)
68. C. Roche-Lestienne, L. Deluche, S. Corm RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance Blood 111 2008 3735 3741
69. H. Sill, J.M. Goldman, N.C. Cross Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia Blood 85 1995 2013 2016
70. C.G. Mullighan, C.B. Miller, I. Radtke BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros Nature 453 2008 110 114 (Pubitemid 351630327)
71. P. Neviani, R. Santhanam, R. Trotta The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 2005 355 368 (Pubitemid 41579831)
72. M. Towatari, K. Adachi, H. Kato, H. Saito Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia Blood 78 1991 2178 2181
73. H.G. Ahuja, P.S. Jat, A. Foti, M. Bar-Eli, M.J. Cline Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia Blood 78 1991 3259 3268
74. Z. Beck, A. Kiss, F.D. Tth Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia Leuk Lymphoma 38 2000 587 597 (Pubitemid 30614544)
75. B. Johansson, T. Fioretos, F. Mitelman Cytogenetic and molecular genetic evolution of chronic myeloid leukemia Acta Haematol 107 2002 76 94 (Pubitemid 34264171)
76. D. Perrotti, V. Cesi, R. Trotta BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2 Nat Genet 30 2002 48 58
77. J.S. Chang, R. Santhanam, R. Trotta High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation Blood 110 2007 994 1003 (Pubitemid 47267439)
78. K. Wagner, P. Zhang, F. Rosenbauer Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy Proc Natl Acad Sci U S A 103 2006 6338 6343
79. B. Schultheis, R. Szydlo, F.X. Mahon, J.F. Apperley, J.V. Melo Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment Blood 105 2005 4893 4894 (Pubitemid 40807320)
80. D.J. Barnes, D. Palaiologou, E. Panousopoulou Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia Cancer Res 65 2005 8912 8919 (Pubitemid 41377381)
81. G. Keller, P. Schafhausen, T.H. Brmmendorf Bosutinib Recent Results Cancer Res 184 2010 119 127
82. K. Beel, A. Janssens, G. Verhoef, P. Vandenberghe Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy Leuk Res 33 2009 1703 1705
83. B. Hanfstein, M.C. Muller, S. Kreil Dynamics of mutant BCR-ABL positive clones after cessation of tyrosine kinase inhibitor therapy Haematologica 96 2011 360 366